You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to August 2024

AbstractFullPdf
Nov 2023334032
Dec 202348011
Jan 202493012
Feb 20245206
Mar 202492015
Apr 2024104016
May 2024118010
Jun 202410407
Jul 2024108015
Aug 202470010
Total11230134